KYORIN Pharmaceutical Co., Ltd.
Notice Regarding Transfer of Generic Pharmaceuticals Business
To transfer the generic pharmaceuticals business to a collaborative organization, a two-step absorption-type split will be carried out, after which the target business will be transferred to the collaborative organization. The effective date is March 31, 2027, and the share transfer is scheduled to be executed on April 1, 2027. This is carried out in the context of implementing the mid-term plan under Vision 110 Stage2.
Key Figures
- Absorption-type split schedule: March 31, 2027 (scheduled)
- Share transfer execution date: April 1, 2027 (scheduled)
- Number of shares held after this share transfer: 0 shares (voting rights ownership ratio: 0%)
AI要約
Overview of the Transaction
KYORIN Pharmaceutical intends to transfer its generic pharmaceuticals business to a collaborative organization by conducting Absorption-Type Split ①, in which the KYORIN Pharmaceutical Group Factory will be the splitting company and the target company will be the successor company, and Absorption-Type Split ②, in which the target company will be the splitting company and the KYORIN Pharmaceutical Group Factory will be the successor company. Subsequently, the issued shares of the target company will be transferred to the collaborative organization. The schedule is: contract conclusion in Q3 of fiscal 2026; effective date March 31, 2027; share transfer execution scheduled for April 1, 2027.
Outlook and Impact
This transaction will optimize the business portfolio and allow the company to concentrate resources on new pharmaceutical businesses, while a special loss associated with the business transfer is expected to be recorded in the second quarter. The specific amount is not yet determined; the company will promptly disclose any matters that should be disclosed. The transaction promotes implementation of the medium-to-long-term plan under Vision 110 -Stage2-.
KYORIN Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
